Clinical Trial Update: A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating per-operative intratumoral autologous myeloid dendritic cells with ipilimumab and nivolumab, followed by repeated intracavitary plus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Autologous myeloid dendritic cells
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING